Abstract:

AIM: To analyze the effect of weekly liposome paclitaxel combined with tiggio on serum tumor markers and soluble e-cadherin (sEC) in elderly patients with advanced gastric cancer. METHODS: Eighty-seven elderly patients with advanced gastric cancer were divided into 41 control groups and 46 treatment groups according to the random number table. In the control group, olififloxacin was intravenously instilled at 130 mg/m2 each time, the first day of each cycle was 21 days, and the course of treatment was continued for 3 courses; tiggio each time 50 mg (body surface area>1.25 m-2-1.5 m-2) or 60 mg (body surface area≥1.5 m-2), oral, 1-28 d per cycle, 6 weeks for 1 course, continuous treatment for 2 courses. The usage of tiggio in the treatment group was the same as that in the control group; the liposome paclitaxel was intravenously infused at 60 mg/m2 each time, at the first, eighth, fifteen, and twenty-second days of the cycle, and one course of treatment was 6 weeks. Then clinical efficacy, serum levels of tumor markers, sEC before and after treatment, adverse reactions and survival in both group were compared.RESULTS:After treatment, the disease control rates in the treatment group and the control group were 65.22% (30/46) and 56.10% (23/46), 1-year survival rate was 58.69% (27/46) and 48.78% (20/41) , there was no statistical difference (P>0.05). Serum levels of carcinoembryonic antigen (CEA) in the treatment group and the control group were (9.37±2.03) and (8.99±1.48) ng/mL, carbohydrate antigen 125 (CA125) was (24.08±3.98) and (23.22±3.86) U/mL, the glucose chain antigen 19-9 (CA19-9) was (14.57±2.81) and (15.30±2.22) U/mL, sEC was (1 903.87±250.17) and (1 934.37±199.46) ng/mL, there was no statistical difference (P>0.05). The adverse reactions in the both groups were mainly nausea and vomiting, anemia, thrombocytopenia, granulocytopenia, diarrhea and liver and kidney dysfunction, adverse reaction rate in treatment group and the control group were statistically significant differences (P<0.05). CONCLUSION:The effect of weekly liposome paclitaxel combined with tiggio on elderly patients with advanced gastric cancer is confirmed, it can reduce the level of serum tumor markers and sEC, and patient tolerance is better.

Key words: advanced gastric cancer in the elderly, liposomes paclitaxel, tiggio, tumor markers, soluble e-cadherin